Gilead Analysts Lift Targets as Stock Slips Into Earnings Window

Short positioning is notably thin and tells little about conviction either way. Short interest at 1.47% of the free float is low by any biotech standard, and it has barely moved this week, up a fraction of a percent on both a daily and weekly basis. What is more interesting is the cost to borrow, which has more than doubled over the past week to 0.70%, though it remains objectively cheap in absolute terms. Availability in the lending market is essentially unlimited, with far more shares available to lend than are currently out on borrow. There is no squeeze setup here and no signal from the short book worth building a thesis around. Options positioning similarly adds little drama: the put/call ratio at 0.56 is marginally above its 20-day average of 0.54, less than one standard deviation elevated. The 52-week high on the PCR is 0.92, so current levels reflect mild caution rather than anything approaching defensive positioning.

Factor scores present a more positive picture. EPS momentum is near the top of the universe, ranking 94th percentile on a 30-day basis and 95th percentile over 90 days. Forward earnings revisions have been moving in the right direction, and the dividend score ranks 97th percentile, reflecting Gilead's well-established payout profile relative to peers. The ORTEX short score has drifted from a recent high of 32.9 at the end of September back to 31.5, a modest improvement. EV/EBITDA has compressed over the past 30 days while the P/E has also come in, the stock having re-rated slightly cheaper even before this week's decline.

The institutional register is concentrated and largely passive. BlackRock recently reported 9.8% of shares, Vanguard Capital Management around 7.1%, and State Street 4.9%. T. Rowe Price added roughly 3.8 million shares in its most recent reported period, a meaningful incremental addition among active managers. No 13D activist filings are on the register, and the 13G holders are all index or passive-adjacent names. There is no activist angle to monitor here.

Insider activity deserves a brief note. CEO Daniel O'Day sold a combined 15,000 shares on October 1 at prices around $147 to $149, though both transactions were made under a pre-arranged 10b5-1 plan, which limits the signalling value. CFO Andrew Dickinson sold 3,000 shares in mid-September, also under a 10b5-1 plan. Net insider activity over the past 90 days shows roughly 105,000 shares sold for approximately $14.9 million in proceeds. Planned sales under Rule 10b5-1 are mechanical rather than discretionary, but the pattern confirms insiders have not been adding to positions at current levels.

The stock's two most recent earnings prints both produced positive immediate reactions, up 1.7% and 0.5% on the day respectively, with five-day moves of 5.7% and 3.5%. With November 6 now 30 days away, the more relevant question heading into that print is whether the Street's confidence in Biktarvy and Yeztugo early adoption holds against any updated guidance on the HIV franchise and oncology ramp, particularly given the gap between analyst targets and where the stock is trading after a weak week.